Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute (Q89241765)
Jump to navigation
Jump to search
scientific article published on 26 October 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute |
scientific article published on 26 October 2014 |
Statements
Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute (English)
S Rule
R Smith
Oklota C Theodore
C A Ngoh
S Osborne
E Capochiani